Puissance Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Puissance Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-9,986	Closed	-$716K	–	7
2018 Q4	$716K	Buy	+9,986	New	+$805K	0.82%	7

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Puissance Capital Management's XBI Position: Q1 2019 in Review

Puissance Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2019, closing a stake of 9,986 shares — an estimated $716K sold.

Puissance Capital Management first reported a position in XBI in Q4 2018 and held it in 1 quarter. The position peaked at $716K in Q4 2018. 451 funds tracked by Wall St. Rank hold XBI as of Q1 2019.

Puissance Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2019 after selling out during the quarter.
Puissance Capital Management sold 9,986 State Street SPDR S&P Biotech ETF shares in Q1 2019, an estimated $716K.
Puissance Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and held it in 1 quarter.
Puissance Capital Management's State Street SPDR S&P Biotech ETF position peaked at $716K in Q4 2018.
451 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2019.

Based on Puissance Capital Management's 13F filing for Q1 2019, filed 14 May 2019.